Chen Xi-Shuang, Liu Hui-Zhen, Huang Fang, Meng Jian, Fang Jing-Xian, Han Yu, Zou Hui-Ming, Gu Qing, Hu Xue, Ma Qian-Wen, Han Yue-Xia, Wang Sui-Jun
Yangpu District Shidong Hospital of Shanghai, Endocrinology and Metabolism, Shanghai, China.
Front Endocrinol (Lausanne). 2025 Sep 1;16:1623136. doi: 10.3389/fendo.2025.1623136. eCollection 2025.
This study aimed to investigate the ameliorative effect of dietary fiber on hepatic fibrosis in T2DM combined with MASLD and to seek the appropriate dose of DF for this population.
This study was a randomized, controlled, open clinical trial. Patients with T2DM and MASLD were recruited from January 2024 to March 2024 in our hospital using the Interactive Web Response System (IWRS) in a 1:1:1 ratio randomly divided into 3 groups. The control patients received traditional diabetes education. Based on health education, the intervention group took DF supplements (Shanghai Jiuben Technology Co., Ltd.) daily for 12 weeks. Each packet of the supplement is 50 grams and contains approximately 12 grams of dietary fiber (DF). The intervention group was randomly assigned to two different groups. One group received 24 grams of fiber, which was obtained by consuming two packets, each containing 12 grams of fiber. The other group received 12 grams of fiber by consuming one packet.
Both interventions showed a more significant decrease in HbA1c levels than the control group, but only the difference between the control and 24g intervention groups was statistically significant(-0.6 ± 0.5 -1.6 ± 0.6, P<.001). The 24g intervention group showed a substantial decrease in FPG compared to the control group and the 12g intervention both at week 8 and week 12 (p < 0.05). Both intervention groups experienced significant reductions in FIB-4 levels (p<0.05), with the intervention with 24g group showing the most significant decrease.
Our study demonstrated that dietary fiber improved liver fibrosis and glycemic control, with a more pronounced effect in patients from the 24g Intervention group. However, this group had no statistically significant change in BMI, possibly due to higher caloric intake from additional fiber.
本研究旨在探讨膳食纤维对2型糖尿病合并代谢相关脂肪性肝病（MASLD）患者肝纤维化的改善作用，并为该人群寻找合适的膳食纤维剂量。
本研究为随机、对照、开放临床试验。2024年1月至2024年3月，利用交互式网络应答系统（IWRS）在我院招募2型糖尿病和MASLD患者，按1:1:1比例随机分为3组。对照组患者接受传统糖尿病教育。在健康教育基础上，干预组患者每天服用膳食纤维补充剂（上海久本科技有限公司），持续12周。每包补充剂为50克，约含12克膳食纤维（DF）。干预组随机分为两个不同组。一组通过食用两包，每包含12克纤维，摄入24克纤维。另一组通过食用一包摄入12克纤维。
两种干预措施均使糖化血红蛋白（HbA1c）水平下降幅度比对照组更显著，但仅对照组与24克干预组之间的差异具有统计学意义（-0.6±0.5 -1.6±0.6，P<0.001）。与对照组和12克干预组相比，24克干预组在第8周和第12周时空腹血糖（FPG）显著下降（p<0.05）。两个干预组的FIB-4水平均显著降低（p<0.05），其中24克干预组下降最为显著。
我们的研究表明，膳食纤维可改善肝纤维化和血糖控制，对24克干预组患者的效果更为明显。然而，该组患者的体重指数（BMI）无统计学意义上的变化，可能是由于额外纤维导致热量摄入增加。
